[Meta] proposal — a flair for co-agonism posts
proposal — a flair for co-agonism posts — with the counter-argument included, because I find it fairly persuasive. Sent a vial to VendorInvestigate because there was almost nothing on file for this compound. 99.6% against a claimed 99.0%, and I posted it because the log needs entries. Combination and monotherapy arms…
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
nothing here is approved as a standalone product and research material is not for human use
amylin and GLP-1 are not redundant pathways
amylin analogue, different receptor family, different story
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.